Ramesh, y ou mentioned revenue guidance h igh single digit, is it in Rupee terms and what's the currency assumptions that you've made?
The other one is there has been some inflationary pressure because of freight and raw material given the Middle E ast crisis. So , what's the annualized impact of the same that you're seeing on the P&L if the situation were to remain at the current level?
We have seen very strong growth in some of the emerging markets like Brazil, South Africa, you mentioned, and also in Europe. How should we think about the growth, because the numbers are very high, so is this number sustainable? And on this pace, how should we think about growth, if you can take us through in these markets, and what will drive that?
So, Vinita, all put together, you're expecting like double digit constant currency growth across all growth across all these key markets?
So Vinita, Nilesh, if you can talk about Semaglutide, other than Canada, which all markets you already filed. And if you can take us through 2026 and 2027, how should we think about the launches? And your preparedness in terms of formulation and API? And how much will be the dependence on partners for this product? So if you can just draw the landscape broadly for this product over the next two years?
And next one was on green propellant. You mentioned Vinita about that opportunity. So how should we think about it? When do we get more clarity on this? And how meaningful this opportunity you see at this point?
So my first question, Vinita, is that for future launches you talked about injectable Glucagon and Dalbavancin. Can you just talk to us about the visibility of these launches and what kind of upside you are expecting from these products?
Particularly on Dalbavancin, is that an exclusive product for you? How are you expecting competitive intensity here?
Just a quick one. Can you share, Vinita, the number of ANDAs filed in this fiscal year?
And is there any reason the intensity of filing has come down this year?
Hi. Thanks for taking my question. Ramesh, if you can like we have got to 20% EBITDA margin. So if you can sketch in terms of markets, which are the ones where you see th e margins much higher than 20% and which are the ones which are sort of lagging behind, and how the dynamics on margins for each of the markets, for the key markets, if you can highlight?
Okay. And any comment on the API business? Because it's small, but it has been a big drag, at least in the recent past I understand.
I just wanted to know, sir, your comments on GST im pact. If you can quantify and also if you can throw some light around various therapy dynamic s in India, how those are growing in the secondary market, please?
So, sir, what was the impact? And what is your guid ance for the full year for India growth now?
Hi sir. Good evening. Sir, the 505 (b)(2) products that you have mentioned, i s it possible to share the opportunity size for these two products in terms of commercial timeline in the US?
And so, you expect it to be probably FY28 or beyond that?
Yeah. Hi, good afternoon, Dr. Sharvin, you know, one question on the specialty business. I just want to understand, you know, what's the P&L impact currently, specifically, if we can highlight the front end expense that you're currently incurring at Sentynl in this financial year and also on the research and development, how much you know you are spending and going forward, you know, how should we think about these spend and in that context we have done some inorganic moves with respect to specialty, any thought, any color you want to because now you have a good cash on books as well. So, if you can just take us through, you know, your thoughts on spending on specialty both in acquisition and through the P&L , what is currently and how you're thinking going forward?
If you can share the numbers Nitin bhai in terms of like R&D spend and also the Sentynl losses if you can highlight for this year?
Yeah, hi. Thanks for taking my question. Sir, just one clarification to start with . Your guidance for next year is consolidated high teen growth or double -digit growth, I just miss ed that and also on the margin, you're expecting it to be flat with Asacol HD competition or you expect it to improve for next year?
And Sir this number that you mention ed is on a consolidated basis , at overall company level , double digit to high teen is what one can expect?
Hello?
Okay-okay. T hanks. And on the landscape for specialty, how are you sort of thinking?
Yes, thanks for taking my question. You know just one question on the, if you can share like what kind of employee strength that Organon has, any indication how it's split between manufacturing, R&D and commercial front-end or geography wise? And I was wondering like this company was spun off not long back and you know they had their own challenges. Do you have any sense of the level of attrition that Organon is facing currently and is that something you need to address to stabilize the business? For further updates and specific queries, please visit www.sunpharma.com or feel free to contact Abhishek Sharma, +91 22 43242929, abhi.sharma@sunpharma.com, Gaurav Chugh, +91 22 43245373, gaurav.chugh@sunpharma.com,
And any comment on attrition?